TLR7:肺腺癌的一个关键预后生物标志物和免疫治疗点
Feiming Hu1, Chenchen Hu1, Yuanli He1,2
1Department of Immunology, The Fourth Military Medical University, Xi'an 710032, China.
Biomedicines
|January 25, 2025
概括
收费类受体7 (TLR7) 是肺腺癌 (LUAD) 的关键预后生物标志物. 较低的TLR7表达与较差的结果相关,但较高的表达预测了对免疫疗法的更好的反应,并确定了用于LUAD治疗的潜在药物候选者.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物信息学是一种生物信息学.
背景情况:
- 瘤微环境 (TME) 显著影响肺腺癌 (LUAD) 的进展.
- 了解LUAD TME中的免疫和 stromal 动力学是复杂的.
- 确定可靠的生物标志物来确定LUAD预后和治疗反应至关重要.
研究的目的:
- 为了分析LUAD TME的免疫和 stromal 组件.
- 在LUAD TME中识别预后生物标志物.
- 探索托尔类受体7 (TLR7) 在LUAD预后和免疫治疗反应中的作用.
主要方法:
- 利用TCGA和GEO数据库来分析瘤微环境组件.
- 使用ESTIMATE算法,PPI网络,COX回归,qPCR,WB和IHC用于生物标志物识别和验证.
- 开发了一种结合TLR7表达的预后诺莫格拉姆模型;分析了免疫细胞透和药物敏感性.
主要成果:
- 发现了TME免疫/风脉组件,临床特征和LUAD预后之间的显著关联.
- 收费类受体7 (TLR7) 被确定为预后生物标志物;较低的表达与较差的结果有关.
- 高TLR7表达与良好的免疫疗法反应 (抗PD-1) 相关联,并确定了潜在的候选药物.
结论:
- TLR7是预测LUAD患者预后和免疫治疗反应的重要临床特征.
- TLR7表达水平为LUAD提供了潜在的治疗策略和候选药物的见解.
- 进一步研究TLR7可能会提高肺腺癌的个性化治疗方法.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.7K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
4.8K
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K